Five RTKs, including human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), c-mesenchymal-epithelial transition factor (c-MET), ROR1, and AXL, are currently known to be targeted by CAR-T cells in BC to elicit therapeutic potential (Fig. 3). This evidence concerns the gene EGFR and breast cancer.